the overuse of analgesics and anti-migraine drugs have been published in recent years, as have up-todate randomized clinical trials on the treatment and prevention of this condition. These new scientific data, as will be discussed in the following sections, provide a basis for recommendations for patient care.
Epidemiology
The prevalence of medication overuse headache in Germany ranges from 0.7% to 1% (5, 6) . Accordingly, 25% to 50% of all patients with chronic headache (i.e., headache on more than 15 days per month) overuse medications (7) . The eTable contains data on the frequency of analgesic and anti-migraine drug overuse in different countries. The figures from the United States of America are accounted for mainly by the overuse of opioids and barbiturates, which are not recommended in Germany for the acute treatment of headache. Women suffer more commonly than men from medication overuse headache, in a ratio of 4:1 (5). The peak prevalence by age is reached in the middle of the fifth decade (8, 9) . The prevalence of medication overuse headache in children lies between 0.3% and 1% (10, 11) .
Diagnosis
The clinical features of analgesic and anti-migraine drug overuse headache depend on the type of primary headache from which the patient suffers. Migraine patients who overuse triptans report daily headaches that generally have the features of a migraine attack, or else an increase in the frequency of migraines (12) ( Table 2 ). As the headaches become more frequent, their phenotype can change as well. In migraine patients, the accompanying vegetative phenomena-nausea, vomiting, photophobia, phonophobia-tend to become less prominent, and the headaches, therefore, can become hard to distinguish from tension headaches. In patients with chronic tension headache who overuse analgesics, the headaches become more frequent, but the clinical features of the dull, pressing holocranial pain do not change (12) . Future studies are needed to provide a well-founded answer to the question whether there are really substance-specific clinical presentations of medication overuse headache. The pathophysiology of medication overuse headache is presented in eBox 1.
The diagnosis of analgesic or anti-migraine drug overuse headache is based on the history and on the documentation of medication use in a headache diary. If headache becomes chronified in a patient over age 60, or if focal neurologic signs or pathological mental changes are found, magnetic resonance imaging of the brain is mandatory. In markedly overweight patients of any age, the cerebrospinal fluid pressure should be measured in order to rule out idiopathic intracranial hypertension ("pseudotumor cerebri") (13) .
Course
The development of analgesic or anti-migraine drug overuse headache over time depends on the substances taken, among other factors. Chronification is faster when triptans and opioids are overused, compared to single analgesics and caffeine-containing combination analgesics (9) . This conclusion can, however, be viewed critically. For each patient, the choice of medication clearly depends to some extent on the severity of the headaches; patients with more severe headaches are more likely to be treated with a combination of triptans and analgesics.
Risk factors
The main risk factors for medication overuse headache are listed in Table 2 . Acetylsalicylic acid as a single substance is not a risk factor.
Treatment
The treatment of analgesic and anti-migraine drug overuse headache consists of three steps (Figure) .
• Step 1 (education and counseling): The patient is informed that the frequent use of analgesics and anti-migraine drugs can lead to the development of chronic headaches. The goal is to limit the consumption of simple analgesics to fewer than 15 days per month, and that of specific analgesics, anti-migraine drugs, and caffeine-containing combined analgesics to fewer than 10 days per month.
• Step 2: Pharmacological and non-pharmacological prophylaxis of the patient's primary headaches is initiated.
• Step 3: If these approaches fail, there should be a drug holiday (drug withdrawal) in an outpatient, day-clinic, or inpatient setting, whichever is most appropriate. Primary headache prophylaxis by pharmacological and non-pharmacological means should continue in parallel. 
Education and counseling
As triptans and analgesics do not cause mental or physical dependence, the term "drug holiday" is preferable to the term "withdrawal." Some patients who overuse medications meet the criteria for addiction, including loss of control, the development of tolerance, and an increasing dose (14) . A meta-analysis of 7 clinical trials involving 391 patients detected no difference between drug holidays in an inpatient setting and drug holidays in an outpatient or day-clinic setting with respect to the reduction of headache days (15) . In the largest trial to date concerning the treatment of medication overuse headache, 379 patients underwent an interdisciplinary three-week outpatient program with medical, psychological, nursing, and physiotherapeutic components. They graded their own headaches on a scale from 0 to 10 before treatment, at the end of the three-week period, and one year later. The mean pain intensities were 6.1, 3.5, and 3.3, respectively (16) . The patients' anxiety and depression scores improved as well.
Migraine prophylaxis
Most of the patients referred to a specialized headache center because of chronic headache due to the overuse of anti-migraine drugs have already received prophylactic medication against migraine attacks, including betablockers, flunarizine, valproic acid, or amitriptyline, without success. It was accepted as dogma until a few years ago that prophylactic drugs against migraine cannot be effective in patients who overuse analgesics and triptans, but two prospective placebo-controlled trials with topiramate have refuted this notion (17) (18) (19) . In both studies, topiramate in doses ranging from 50 to 200 mg per day was significantly more effective than placebo in patients with chronic migraine and medication overuse. In the first trial, the mean number of migraine days in four weeks was 15.5 in the topiramate group (n = 32) and 16.4 in the placebo group (n = 27). After a mean of 90 days, the number of migraine days per month under treatment with topiramate was reduced by 3.5 ± 6.3, compared to -0.2 ± 4.7 for placebo (p < 0.05) (17) . The second trial included 306 patients with chronic migraine (topiramate, n = 153; placebo, n = 153), 38% of whom met the criteria for medication overuse. The responder rate for a 25% reduction of the number of migraine days per month was 68.6% for topiramate vs. 51.6% for placebo (p = 0.005); the corresponding rates for a 50% reduction were 37.3% vs. 28.8% (p = 0.093) (18) . It must be kept in mind, however, that topiramate may exacerbate mental comorbidities, which are common in patients with chronic migraine and medication overuse (20) . In the two large-scale approval trials of onabotulinum toxin A for patients with chronic migraine, 65% of the patients met the criteria for medication overuse headache (21) . Patients who overused barbiturates and opioids were excluded from these trials. The patients in the medication overuse headache subgroup achieved the same degree of therapeutic success (onabotulinum toxin A versus placebo) as patients without medication overuse (22) . Smaller studies have addressed the putative efficacy of valproic acid, cannabinoids, pregabalin, and acupuncture against medication overuse headache, but none of them were of sufficient methodological quality to justify a recommendation for any of these pharmacological or non-pharmacological approaches. Randomized trials are now in progress to study the efficacy of antibodies against calcitonin-gene related peptide (CGRP) or the CGRP receptor in patients with chronic headache due to overuse of analgesics and anti-migraine agents.
The treatment of headache and vegetative symptoms during drug holidays
Patients with medication overuse headache who undergo a drug holiday often have more intense headaches at first. Symptoms of vegetative dysfunction, such as nausea and vomiting, agitation, anxiety, and sleep disturbances, may arise and are sometimes severe. In a systematic review of the literature, 27 studies of the treatment of such symptoms were identified (23) . The recommended measures included fluid replacement, analgesics, antipsychotic drugs to suppress nausea and vomiting, and dihydroergotamine (DHE), which is not approved in Germany. The Norwegian and German placebo-controlled trials of corticosteroids in this setting revealed no therapeutic effect (24, 25) , but both were methodologically inadequate. The heterogeneous patient groups that were studied in the outpatient and inpatient settings had different comorbidities and different accompanying treatments, and these factors may have masked a real effect of steroid treatment. The efficacy of steroids during drug holidays is commonly observed in routine clinical practice, notwithstanding the study findings. Acetysalicylic acid can be given intravenously to combat pain peaks during drug holidays in patients who previously overused triptans. Clinical experience supports the withholding of analgesics (as much as possible), oral or intravenous steroid administration, and at least temporary treatment with tricyclic antidepressants (administered orally or intravenously, depending on the severity of symptoms), as well as antiemetic treatment. This approach has not been validated to date by any randomized controlled clinical trial. An evaluation of observational data revealed that the severity and duration of symptoms during a drug holiday depends to a large extent on the particular substance that was overused. If triptans or analgesics alone were overused, the symptoms can usually be well controlled and subside within one week. In contrast, a drug holiday after the overuse of ergotamines, combinations of triptans and analgesics, or caffeine-containing combined analgesics usually leads to prolonged symptoms (26) . In this situation, adequate treatment to suppress nausea and vomiting and sometimes the short-term use of neuroleptic drugs have proven useful in routine clinical practice. If the overused drug was an opioid (usually tilidine or tramadol), especially in a slow-release form, true withdrawal phenomena can arise, including signs of autonomic decompensation. Opioids and barbiturates should not be abruptly discontinued, but rather tapered to off. Tachycardia and hypertension as symptoms of withdrawal can be effectively treated in a monitored inpatient setting with the α2-adrenoceptor antagonist clonidine (27) .
The effects of drug holidays
In a large-scale international trial in Europe and South America that included 376 patients with medication overuse headache, analgesics and acute anti-migraine drugs were discontinued and prophylaxis against migraine attacks was given. Six months into the trial, twothirds of the patients were no longer overusing acute medication, and the chronic headache had regressed to an episodic headache in 50% (28) . Over this period, depression and anxiety were also reduced, and the patients experienced less impairment as the result of their headaches. It remains unclear whether prophylactic drug treatment should be started before, during, or after the drug holiday. In Denmark, headache specialists generally wait to observe the success of the drug holiday and then begin anti-migraine prophylaxis after an interval of three to six months; in Germany, most patients are started on anti-migraine prophylactic drugs immediately before, or simultaneously with, the discontinuation of analgesics or anti-migraine drugs. This pragmatic approach is motivated by the consideration that patients with chronic headache have high relapse rates and their symptoms can be suppressed in the inpatient setting to an extent that enables them to take part in a treatment program (eBox 2).
Recurrence
In a systematic review of 22 studies with follow-up intervals ranging from 2 to 60 months and a mean follow-up interval of 12 months, the mean recurrence rate ranged from 25% to 35% (23) . Predictors of recurrence of medication overuse headache included chronic tension headache as opposed to migraine, the overuse of opioids as opposed to triptans, and psychiatric comorbidities. Post-trial observations in a cohort of patients who underwent headache treatment in a day clinic at the Universitäts klinikum in Essen have shown that patient education and counseling, as part of a structured treatment program in a day clinic, can lower the recurrence rate of medication overuse headache to less than 10% (29) .
Prevention
The most effective way to prevent medication overuse headache is to identify patients at risk and to educate them about the use of acute medication. The risk is higher in patients with frequent headaches (10-14 headache days per month, high-frequency episodic migraine) than in those with rarer headaches (1-9 headache days per month, low-frequency episodic migraine). Likewise, patients with chronic headache, i.e., headache on at least 15 days per month, are also at high risk of developing medication overuse headache if they take acute medication on an increasing number of headache days. If opioids are taken, the risk is much higher; such patients should be identified early so that they can be treated with preventive strategies (30) . A randomized trial revealed the efficacy of patient education, either with an informational brochure or with group therapy based on cognitive behavioral therapy, in preventing medication overuse headache (31) . Pharmacists, too, should identify and appropriately counsel patients at risk; this is especially important in view of the fact that two different triptans, like most analgesics, can now be obtained in Germany without a prescription. Both general practitioners and specialists should implement mechanisms in their practices for the reliable detection of any increasing need for acute medication or higher demand for prescriptions in headache patients.
Critical evaluation of the concept of medication overuse headache
The concept of medication overuse headache is debated in the current literature. The valid objection has been raised that longitudinal studies of large patient cohorts are lacking and that some of the affected patients do not benefit from a drug holiday. The causal relationship between medication use and increased headache frequency has not been proven. Medication overuse is but one of the many risk factors for chronification that may be of varying importance in individual cases, yet the concept of the drug holiday takes insufficient account of this fact. New treatments need to be developed, above all, for those patients who fail to respond to the recommended treatments for medication overuse headache and whose headaches do not improve after their medications are discontinued (32) . 
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Erratum
In the Editorial accompanying two articles on the consumption of e-cigarettes in Germany, which appeared in issue 14 of Deutsches Ärzteblatt International, dated 6 April 2014, it was stated that "More than 90% of the e-cigarette market is in the hands of major tobacco companies." This statement is not correct. These companies' share of the market for conventional cigarettes is approximately 90%; their share of the market for e-cigarettes is probably much smaller. 
